Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-EN Version v3-EN
Language English English
Date Updated 2020-08-19 2020-07-31
Drug Identification Number 02447401 02447401
Brand name OBIZUR OBIZUR
Common or Proper name Antihemophilic Factor (Recombinant), Porcine Sequence Antihemophilic Factor (Recombinant), Porcine Sequence
Company Name TAKEDA CANADA INC TAKEDA CANADA INC
Ingredients ANTIHEMOPHILIC FACTOR ANTIHEMOPHILIC FACTOR
Strength(s) 500UNIT 500UNIT
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 3 mL single-dose vial 3 mL single-dose vial
ATC code B02BD B02BD
ATC description VITAMIN K AND OTHER HEMOSTATICS VITAMIN K AND OTHER HEMOSTATICS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2020-07-30 2020-07-30
Actual start date 2020-07-30 2020-07-30
Estimated end date 2020-09-15 2020-09-15
Actual end date 2020-08-18
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments